SEC Form 4 · accession 0001209191-15-032911

Eiger BioPharmaceuticals, Inc. · EIGR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Krisztina M Zsebo

Officer — Chief Executive Officer · Director

Period of report

Apr 6, 2015

Accepted (ET)

Apr 7, 2015 · 4:38 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001305253

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Apr 6, 2015	M	41,302	$1.12	A	44,427	D
Common Stock^F1	Apr 6, 2015	M	6,629	$8.00	A	51,056	D
Common Stock^F3,F1	Apr 6, 2015	S	41,302	$18.16	D	9,754	D
Common Stock^F4,F1	Apr 6, 2015	S	6,629	$18.44	D	3,125	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F5	$1.12	Apr 6, 2015	M	41,302	D	Jan 27, 2013	Jun 14, 2022	Common Stock	41,302	652,346	D
Stock option (right to buy)^F6	$8.00	Apr 6, 2015	M	6,629	D	Jan 29, 2015	Jan 28, 2024	Common Stock	6,629	645,717	D

Explanation of responses

F1The amount includes shares purchased under Celladon Corporation's employee stock purchase plan prior to the reported transaction.
F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 20, 2014.
F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.55 to $18.98 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.89 to $18.97 per share, inclusive. The reporting person undertakes to provide to Celladon Corporation, any security holder of Celladon Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F525% of the shares subject to the option vested and became exercisable on the one year anniversary of January 27, 2012 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.
F625% of the shares subject to the option vested and became exercisable on the one year anniversary of January 29, 2014 (the "Vesting Commencement Date"), and 1/48th of the shares vest in equal monthly installments thereafter, over the remaining three years.